References
- Volanakis JE. Human CRP: Expression, structure, and function. Mol Immunol 2001; 38: 189–197
- Tillett WS, Francis T, Jr. Serological reactions in pneumonia with a non-protein fraction of pneumococcus. J Exp Med 1930; 52: 561–571
- Shrive AK, Cheetham GM, Holden D, Myles DA, Turnell WG, Volanakis JE, Pepys MB, Bloomer AC, Greenhough TJ. Three dimensional structure of human CRP. Nat Struct Biol 1996; 3: 346–354
- Bang R, Marnell L, Mold C, Chivington-Buck C, Du Clos KT, Du Clos TW. Analysis of binding sites in human CRP for FcγRI, FcγRIIa and C1q by site-mediated mutagenesis. J Biol Chem 2005; 280: 25095–25102
- Marnell L, Mold C, Du Clos TW. CRP: Ligands, receptors and role in inflammation. Clin Immunol 2005; 117: 104–111
- Du Clos TW, Zlock LT, Rubin RL. Analysis of the binding of CRP to histones and chromatin. J Immunol 1988; 141: 4266–4270
- Jewell WS, Marnell LL, Rokeach LA, Du Clos TW. CRP binding to the Sm-D protein of snRNPs. Identification of a short polypeptide binding region. Mol Immunol 1993; 30: 701–708
- Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by CRP. Immunopharmacology 1999; 42: 23–30
- Mold C, Rodic-Polic B, Du Clos TW. Protection from Streptococcus pneumoniae infection by CRP and natural antibody requires complement but not Fcγ receptors. J Immunol 2002; 168: 6375–6381
- Mold C, Rodriguez W, Rodic-Polic B, Du Clos TW. CRP mediates protection from lipopolysaccharide through interactions with FcγR. J Immunol 2002; 169: 7019–7025
- Gershov D, Kim S, Brot N, Elkon KB. CRP binds to apo cells, protects the cells from assembly of the terminal complement components, and sustains an anti-inflammatory innate immune response: Implications for systemic autoimmunity. J Exp Med 2000; 192: 1353–1363
- Abou-Raya A, Abou-Raya S. Inflammation: A pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006; 5: 331–337
- Borg EJ, Horst G, Limburg PC, van Rijswijk MH, Kallenberg CG. CRP levels during disease exacerbation and infections in SLE: A prospective longitudinal study. J Rheumatol 1990; 17: 1642–1648
- Vogt B, Führnrohr B, Müller R, Sheriff A. CRP and the disposal of dying cells: Consequences for SLE and rheumatoid arthritis. Autoimmunity 2007; 40: 295–298
- Szalai AJ, Weaver CT, McCrory MA, van Ginkel FW, Reiman RM, Marion TN, Volanakis JE. Delayed lupus onset in (NZB × NZW)F1 mice expressing a human CRP transgene. Arthritis Rheum 2003; 48: 1602–1611
- Edberg JC, Wu J, Langefeld CD, Brown EE, Marion MC, McGwin G, Jr., Petri M, Ramsey-Goldman R, Reveille JD, Frank SG, Kaufman KM, Harley JB, Alarcón GS, Kimberly RP. Genetic variation in the CRP promoter: Association with SLE. Hum Mol Genet 2008; 17: 1147–1155
- Figueiredo MA, Rodriguez A, Ruiz-Yague M, Romero M, Fernandez-Cruz A, Gomez-de la Concha E, Patiño R. AAb against CRP: Clinical associations in SLE and primary antiphospholipid syndrome. J Rheumatol 2006; 33: 1980–1986
- Lee S-S, Singh S, Magder LS, Petri M. Predictors of high sensitive CRP levels in patients with SLE. Lupus 2008; 17: 114–123
- Lee S-S, Singh S, Link K, Petri M. High-sensitivity CRP as an associate of clinical and organ damage in SLE. Semin Arthritis Rheum 2008, in press
- Barnes EV, Narain S, Naranjo A, Shuster J, Segal MS, Sobel ES, Armstrong AE, Santiago BE, Reeves WH, Richards HB. High sensitivity CRP in SLE: Relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005; 14: 576–582
- Ames PRJ, Antinolfi I, Ciampa A, Batuca J, Scenna G, Lopez LR, Delgado Alves J, Iannaccone L, Matsuura E. Primary antiphospholipid syndrome. A low grade auto-inflammatory disease?. Rheumatology (Oxford) 2008; 47: 1832–1837